These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11097340)

  • 1. Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants.
    Nebert DW
    Clin Chem Lab Med; 2000 Sep; 38(9):857-61. PubMed ID: 11097340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of drug metabolism.
    Nebert DW; Dieter MZ
    Pharmacology; 2000 Sep; 61(3):124-35. PubMed ID: 10971198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
    Nebert DW; McKinnon RA; Puga A
    DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues.
    Nebert DW; Ingelman-Sundberg M; Daly AK
    Drug Metab Rev; 1999 May; 31(2):467-87. PubMed ID: 10335448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer.
    Neber DW; Roe AL
    Sci Total Environ; 2001 Jul; 274(1-3):93-102. PubMed ID: 11453308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance.
    Puga A; Nebert DW; McKinnon RA; Menon AG
    Crit Rev Toxicol; 1997 Mar; 27(2):199-222. PubMed ID: 9099519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis of hepatic enzyme activities of drug metabolizing enzymes-phenotyping and genotyping].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1999; (117):63-76. PubMed ID: 10859937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genetic polymorphisms on drug metabolizing enzymes in relation to anti-cancer drug effectiveness].
    Ozawa S
    Rinsho Byori; 2003 Feb; 51(2):168-73. PubMed ID: 12690635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and Phase II enzyme polymorphisms and childhood cancer.
    Swinney R; Hsu S; Tomlinson G
    J Investig Med; 2006 Sep; 54(6):303-20. PubMed ID: 17134614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
    Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
    Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic polymorphisms and cancer susceptibility.
    Smith G; Stanley LA; Sim E; Strange RC; Wolf CR
    Cancer Surv; 1995; 25():27-65. PubMed ID: 8718512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicogenetic profile and cancer risk in Lebanese.
    Dhaini HR; Kobeissi L
    J Toxicol Environ Health B Crit Rev; 2014; 17(2):95-125. PubMed ID: 24627976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer therapy and polymorphisms of cytochromes P450.
    MacLeod SL; Nowell S; Massengill J; Jazieh A; McClure G; Plaxco J; Kadlubar FF; Lan NP
    Clin Chem Lab Med; 2000 Sep; 38(9):883-7. PubMed ID: 11097344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytochromes P450: xenobiotic metabolism, regulation and clinical importance].
    Guéguen Y; Mouzat K; Ferrari L; Tissandie E; Lobaccaro JM; Batt AM; Paquet F; Voisin P; Aigueperse J; Gourmelon P; Souidi M
    Ann Biol Clin (Paris); 2006; 64(6):535-48. PubMed ID: 17162257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of human cytochrome P-450s in risk assessment and susceptibility to environmentally based disease.
    Gonzalez FJ; Gelboin HV
    J Toxicol Environ Health; 1993; 40(2-3):289-308. PubMed ID: 8230303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.
    Stingl JC; Brockmöller J; Viviani R
    Mol Psychiatry; 2013 Mar; 18(3):273-87. PubMed ID: 22565785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.